Psoriatic Arthritis
Direct switch from TNFi to tofacitinib shows ‘acceptable’ safety in psoriatic arthritis
For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no increased safety risks, according to data published in Arthritis Research & Therapy.
Celltrion's Steqeyma nabs FDA approval as seventh Stelara biosimilar
The FDA has approved the Stelara biosimilar Steqeyma for the treatment of adults and children with plaque psoriasis and psoriatic arthritis and adults with Crohn’s disease and ulcerative colitis, Celltrion announced in a press release.
Withholding methotrexate after zoster vaccine ‘shows promise’ in raising humoral response
WASHINGTON — Patients with autoimmune rheumatic diseases who withhold methotrexate for 2 weeks after receiving the recombinant herpes zoster vaccine demonstrate improved humoral response, according to data presented at ACR Convergence 2024.
Johnson & Johnson submits sBLAs for Tremfya for two pediatric indications
Johnson & Johnson has submitted two supplemental biologics license applications to the FDA for Tremfya for the treatment of plaque psoriasis and juvenile psoriatic arthritis in children, the company announced in a press release.
FDA approves Yesintek, sixth Stelara biosimilar; launch slated for February
The FDA has approved the Stelara biosimilar Yesintek for indications matching the reference product, with a commercial launch date expected for early 2025, according to a press release from Biocon Biologics.
IL-6, JAK inhibitors, rituximab increase severe infection risk in inflammatory arthritis
WASHINGTON — Patients with inflammatory arthritis who receive rituximab, interleukin-6 inhibition or Janus kinase inhibitors demonstrate higher severe infection risks vs. TNF inhibitors, according to data presented at ACR Convergence 2024.
Patients ‘very skilled’ at monitoring own non-musculoskeletal psoriatic arthritis features
WASHINGTON — Dactylitis, psoriasis and other non-musculoskeletal manifestations of psoriatic arthritis can be accurately monitored through patient self-reporting, according to data presented at ACR Convergence 2024.
Hand, whole-body MRI register joint, enthesis improvements from apremilast in PsA
Hand and whole body MRI can objectively measure improvements in joint and enthesis inflammation resulting from apremilast treatment for psoriatic arthritis, according to data published in The Lancet Rheumatology.
Deucravacitinib superior to placebo for achieving psoriatic arthritis MDA at 16 weeks
Deucravacitinib is superior to placebo for improving response across all domains of minimal disease activity criteria in patients with psoriatic arthritis at 16 weeks, according to data published in Rheumatology.
World Psoriasis Day: Top Healio stories highlight challenges of disease
Around the world, approximately 125 million people suffer from psoriasis and psoriatic arthritis. On Oct. 29, World Psoriasis Day, we recognize the challenges of and treatment advances for patients with psoriasis.